Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: AIN457 (secukinumab)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals